Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12801MR)

This product GTTS-WQ12801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12801MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9757MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ3167MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ2836MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ4386MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ13550MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ2416MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ13021MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ1906MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGEN2034
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW